Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (122)	10/4/2001 1:48:35 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 138

FDA OKs Hollis-Eden Phase II Hepatitis B Drug Trial Dow Jones Newswires SAN DIEGO -- Hollis-Eden Pharmaceuticals Inc. (HEPH) received approval to begin a Phase II clinical trial of its immune regulating hormone product for the treatment of hepatitis B. In a press release Thursday, the development-stage pharmaceutical company said the clinical study will evaluate the safety, tolerance, clinical and biological effects of HE2000 in young patients infected with the hepatitis B virus at Mt. Elizabeth Medical Centre in Singapore. Company representatives weren't immediately available for further details. The company is also testing the investigational drug as a treatment for malaria in Thailand. Hollis-Eden shares recently traded at $7.25, up 22 cents or 3.1%, on Nasdaq volume of 6,900 shares. Average volume is 26,167 shares. Company Web site: holliseden.com

To: Jim Oravetz who wrote (122)	11/26/2001 1:47:15 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 138

Hollis-Eden:Immune Regulating Hormone Pdt Study Positive SAN DIEGO -- Hollis-Eden Pharmaceuticals Inc. (HEPH) found that HE2200, an immune regulating hormone drug candidate, was generally well tolerated by the patients in a Phase I clinical study. In a press release Monday, the company said HE2200 was subcutaneously administered in healthy young and elderly adult volunteers. Hollis-Eden also received clearance from the Food and Drug Administration to begin a similar Phase I human clinical trial with HE2200 using a buccal tablet formaulation. Preclinical studies with HE2200 have indicated the compound has the potential to provide benefit in a variety of settings of immune dysregulation including inflammatory bowel disease, age-related loss of immunity and radiation-induced immune suppression. Hollis-Eden plans to conduct Phase II clinical studies related to one or more of these areas. Company Web site: holliseden.com